Isosteviol sodium protects the cardiomyocyte response associated with the SIRT1/PGC‐1α pathway. Issue 18 (5th August 2020)

• Record Type: Journal Article
• Authors: Mei, Ying; Liu, Bo; Su, Hao; Zhang, Hao; Liu, Fei; Ke, Qingjin; Sun, Xiaoou; Tan, Wen
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 18(2020)
• Page Start: 10866
• Page End: 10875
• Publication Date: 2020-08-05
• Subjects: cardiomyocyte dysfunction -- isosteviol sodium -- mitochondria -- PGC‐1α -- SIRT1; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.15715
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Cardiomyocyte dysfunction is attributed to excess oxidative damage, but the molecular pathways involved in this process have not been completely elucidated. Evidence indicates that isosteviol sodium (STVNa) has cardioprotective effects. We therefore aimed to identify the effect of STVNa on cardiomyocytes, as well as the potential mechanisms involved in this process. We established two myocardial hypertrophy models by treating H9c2 cells with high glucose (HG) and isoprenaline (ISO). Our results showed that STVNa reduced H9c2 mitochondrial damage by attenuating oxidative damage and altering the morphology of mitochondria. The results also indicated that STVNa had a positive effect on HG‐ and ISO‐induced damages via mitochondrial biogenesis. The protective effects of STVNa on cardiomyocytes were associated with the regulation of the SIRT1/PGC‐1α signalling pathway. Importantly, the effects of STVNa involved different methods of regulation in the two models, which was confirmed by experiments using an inhibitor and activator of SIRT1. Together, the results provide the basis for using STVNa as a therapy for the prevention of cardiomyocyte dysfunctions.